A recent study attempted to explore the genomic characteristics of the PI3K pathway activated in NSCLC patients following progression on EGFR-TKIs and the co-occurrence of common mutations through PI3K–AKT–mTOR. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.